We are live on ! Find out more
TCRT icon

Alaunos Therapeutics
TCRT

148 hedge funds and large institutions have $65.9M invested in Alaunos Therapeutics in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 41 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,587% more call options, than puts

Call options by funds: $5.45M | Put options by funds: $203K

0.13% less ownership

Funds ownership: 0.44% → 0.31% (-0.13%)

10% less funds holding

Funds holding: 165 → 148 (-17)

24% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 41

48% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 33

58% less capital invested

Capital invested by funds: $156M → $65.9M (-$89.9M)

Holders
148
Holders Change
-17
Holders Change %
-10.3%
% of All Funds
2.33%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
17
Increased
31
Reduced
41
Closed
33
Calls
$5.45M
Puts
$203K
Net Calls
+$5.25M
Net Calls Change
-$20.8M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$3.48M
2
N
Nuveen
North Carolina
+$649K
3
DCM
Discovery Capital Management
Connecticut
+$570K
4
Renaissance Technologies
Renaissance Technologies
New York
+$387K
5
GCP
GSA Capital Partners
United Kingdom
+$199K

Top Sellers

Rank Fund Capital Flow
1
MP
MSD Partners
New York
-$25.9M
2
State Street
State Street
Massachusetts
-$6.93M
3
Millennium Management
Millennium Management
New York
-$1.15M
4
Rafferty Asset Management
Rafferty Asset Management
New York
-$889K
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$824K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIP
101
Ameritas Investment Partners
Nebraska
$12K – – –
NAS
102
Nicolet Advisory Services
Wisconsin
$11K – – –
TRCT
103
Tower Research Capital (TRC)
New York
$11K +$3.98K +31 +37%
Wolverine Trading
104
Wolverine Trading
Illinois
$11K +$14.1K +110 New
AWM
105
Altium Wealth Management
New York
$10K – – –
Prudential Financial
106
Prudential Financial
New Jersey
$10K – – –
RJFSA
107
Raymond James Financial Services Advisors
Florida
$9K -$6.03K -47 -34%
US Bancorp
108
US Bancorp
Minnesota
$9K +$3.85K +30 +48%
Cerity Partners
109
Cerity Partners
New York
$9K +$11.7K +91 New
MAM
110
Meeder Asset Management
Ohio
$9K +$13K +101 New
Canada Life
111
Canada Life
Manitoba, Canada
$8K – – –
CPO
112
Cerity Partners OCIO
New York
$8K – – –
HCM
113
Hudson Capital Management
New Jersey
$8K – – –
KAS
114
Kestra Advisory Services
Texas
$8K – – –
SFI
115
SPC Financial Inc
Maryland
$8K – – –
BF
116
BOK Financial
Oklahoma
$7K – – –
FCH
117
Freestone Capital Holdings
Washington
$7K – – –
Mackenzie Financial
118
Mackenzie Financial
Ontario, Canada
$7K – – –
ODG
119
O'Dell Group
Ohio
$7K – – –
PPW
120
Pasadena Private Wealth
California
$7K – – –
X
121
Xponance
Pennsylvania
$7K +$8.73K +68 New
MFG
122
Magnus Financial Group
New York
$7K +$9.37K +73 New
CPIG
123
Chicago Partners Investment Group
Illinois
$7K +$12.1K +94 New
ADL
124
Asset Dedication LLC
California
$6K – – –
BCV
125
Banque Cantonale Vaudoise
Switzerland
$5K -$12.4K -97 -64%
3 4
5
6 7

TCRT Hedge Fund Activity: Q1 2022 in Review

148 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q1 2022, worth a combined $65.9M — down 58% from $156M a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of TCRT and 17 opened new positions — a net loss of 16 holders — while 41 trimmed existing stakes and 31 added.

The largest buyer was Goldman Sachs, adding an estimated $3.48M. The largest seller was MSD Partners, cutting an estimated $25.9M.

  • 148 institutional investors held Alaunos Therapeutics (TCRT) as of Q1 2022, down from 165 in Q4 2021.
  • Funds reported $65.9M of Alaunos Therapeutics stock for Q1 2022, down 58% quarter-over-quarter.
  • 17 funds opened new Alaunos Therapeutics positions in Q1 2022 and 33 closed out, a net change of -16 holders.
  • The largest Alaunos Therapeutics buyer in Q1 2022 was Goldman Sachs, an estimated $3.48M added.
  • The largest Alaunos Therapeutics seller in Q1 2022 was MSD Partners, an estimated $25.9M sold.

Based on aggregated 13F filings for Q1 2022.